Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Follow-Up Questions
Tỷ lệ P/E của Phathom Pharmaceuticals Inc (PHAT) là bao nhiêu?
Tỷ lệ P/E của Phathom Pharmaceuticals Inc là N/A
Hiệu suất giá của cổ phiếu PHAT như thế nào?
Giá hiện tại của PHAT là 11.75, đã increased 0.04% trong ngày giao dịch cuối cùng.
Vốn hóa thị trường của Phathom Pharmaceuticals Inc là bao nhiêu?
Vốn hóa thị trường hiện tại của Phathom Pharmaceuticals Inc là $833.8
Có nên mua, bán hay nắm giữ Phathom Pharmaceuticals Inc?
Theo các nhà phân tích phố Wall, 10 nhà phân tích đã đưa ra xếp hạng phân tích cho Phathom Pharmaceuticals Inc, bao gồm 5 mua mạnh, 8 mua, 2 nắm giữ, 0 bán, và 5 bán mạnh
